Sugi Predict

Sugi Predict / Compounds / SCHEMBL1758718

SCHEMBL1758718

SCHEMBL1758718

CC(C)(C)c1cc(NC(=O)O)no1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 1/20 0.66
▸ NPC1 O15118 6/20 0.65
▸ RAB9A P51151 6/20 0.65
▸ KMT2A Q03164 3/20 0.65
▸ MEN1 O00255 2/20 0.65
▸ LMNA P02545 1/20 0.61
▸ POLB P06746 1/20 0.61
▸ SMN1; SMN2 Q16637 4/20 0.60
▸ HTT P42858 3/20 0.60
▸ PKM P14618 1/20 0.60
▸ TSHR P16473 1/20 0.60
▸ MAPK14 Q16539 3/20 0.59
▸ HPGD P15428 1/20 0.57
▸ TDP1 Q9NUW8 1/20 0.56
▸ FLT3 P36888 2/20 0.56
▸ GAA P10253 1/20 0.56
▸ MAPT P10636 2/20 0.55
▸ NPSR1 Q6W5P4 1/20 0.55
▸ MAPK13 O15264 1/20 0.55
▸ RAF1 P04049 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2951112 0.87 RAB9A (0.77) EGFRNPC1RAB9AKMT2AMEN1
SCHEMBL27218027 0.86 NPC1 (0.50) EGFRNPC1RAB9AKMT2AMEN1
SCHEMBL4112548 0.85 EGFR (0.66) EGFRNPC1RAB9AKMT2AMEN1
SCHEMBL9891521 0.84 EGFR (0.64) EGFRNPC1RAB9AKMT2AMEN1
SCHEMBL11158107 0.84 EGFR (0.69) EGFRNPC1RAB9AKMT2AMEN1
SCHEMBL4543722 0.84 EGFR (0.64) EGFRNPC1RAB9AKMT2AMEN1
SCHEMBL1078864 0.83 NPC1 (0.48) EGFRNPC1RAB9AKMT2AMEN1
SCHEMBL18763512 0.83 EGFR (0.51) EGFRNPC1RAB9AKMT2AMEN1
SCHEMBL25567697 0.83 EGFR (0.59) EGFRNPC1RAB9AKMT2AMEN1
SCHEMBL14422913 0.83 EGFR (0.72) EGFRNPC1RAB9AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2496584-B1 PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES AMBIT BIOSCIENCES CORP (US) 2016-09-21 — — EP claimed
US-9284332-B2 Process for the preparation of imidazo[2,1-B][1,3]benzothiazole derivatives AMBIT BIOSCIENCES CORPORATION (US) 2016-03-15 — — US claimed
US-20130005966-A1 PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES AMBIT BIOSCIENCES CORP. (US) 2013-01-03 — — US claimed
EP-2496584-A1 PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES Ambit Biosciences Corp. (US) 2012-09-12 — — EP claimed
WO-2011056939-A1 PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES AMBIT BIOSCIENCES CORP. (US) 2011-05-12 — — WO claimed
US-4116671-A HERBICIDES SHIONOGI & CO., LTD. (JP) 1978-09-26 — — US claimed
EP-4146348-B1 INHIBITORS OF NEK7 KINASE HALIA THERAPEUTICS INC (US) 2024-07-03 — — EP disclosed
US-20240158394-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2024-05-16 — — US disclosed
WO-2024059200-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. (US) 2024-03-21 — — WO disclosed
US-20230416259-A1 INHIBITORS OF NEK7 KINASE HALIA THERAPEUTICS INC (US) 2023-12-28 — — US disclosed
WO-2023237759-A1 DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR ANAGENESIS BIOTECHNOLOGIES (FR) 2023-12-14 — — WO disclosed
EP-4289427-A1 DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR. Anagenesis Biotechnologies (FR) 2023-12-13 — — EP disclosed
CN-116874967-A Composition, polymer composite article formed therewith, and method of making the same 美国陶氏有机硅公司 2023-10-13 — — CN disclosed
US-20080027076-A1 Pyrimidines With Tie2 (Tek) Activity ASTRAZENECA AB (SE) 2008-01-31 — — US disclosed
EP-1848715-A1 COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY AstraZeneca AB (SE) 2007-10-31 — — EP disclosed
EP-1737463-A1 PYRIMIDINES WITH TIE2 (TEK) ACTIVITY AstraZeneca AB (SE) 2007-01-03 — — EP disclosed
EP-1737462-A1 PYRIMIDINES WITH TIE2 (TEK) ACTIVITY AstraZeneca AB (SE) 2007-01-03 — — EP disclosed
WO-2006082404-A1 COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY ASTRAZENECA AB (SE) 2006-08-10 — — WO disclosed
WO-2005060969-A1 PYRIMIDINES WITH TIE2 (TEK) ACTIVITY ASTRAZENECA AB (SE) 2005-07-07 — — WO disclosed
WO-2005060970-A1 PYRIMIDINES WITH TIE2 (TEK) ACTIVITY ASTRAZENECA AB (SE) 2005-07-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005966-A1 PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES FLT4, FLT1, FLT3 EGFR 712/4885NPC1 2716/4885RAB9A 3772/4885
US-20240158394-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 EGFR 4857/4885NPC1 241/4885RAB9A 3372/4885
US-20230416259-A1 INHIBITORS OF NEK7 KINASE NEK7, NEK1, NEK5 EGFR 4553/4885NPC1 414/4885RAB9A 2987/4885
US-20080027076-A1 Pyrimidines With Tie2 (Tek) Activity TIE1, TEK, TEKT1 EGFR 369/4885NPC1 4792/4885RAB9A 4665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.